MGUS individuals
optimal MGUS follow-up
prior knowledge of MGUS
screening study
years
population-based study
routine screening
low-risk patients
impact of screening
individual patients
individual risk of progression
randomized clinical trial Monoclonal gammopathy of undetermined significance
new risk model
optimal work
Iceland
superior survival
overall survival
optimal monitoring
prospective study
retrospective data
Current risk stratification schemes
follow-up strategy
biological correlation
germline genetic markers
serum protein markers
different arms
free light chain analyses
evidence
common precursor condition
multiple myeloma
scientific implications
electrophoresis
imaging
blood
outcome
question
fact
various reasons
present infrastructure
age
related diseases